Abstract
Biologic treatments have modified the therapeutic armamentarium in the treatment of many dermatological and non- dermatological diseases and data on literature have widely focused on the efficacy and safety of TNF-alpha inhibitors in psoriasis.
Although the etiopathogenesis has not completely elucidated, inflammation appears the lait motif unifying the immune-pathogenesis of diverse skin disease, as atopic dermatitis, alopecia areata and hidradenitis suppurativa.
Actually, data on the off-label use of biologics in cutaneous immune-mediated inflammatory diseases are scarce and restricted to anecdotal cases and case series.
The present review aims to evidence the major off- label use of TNF-alpha inhibitors in dermatology.
Keywords: Inflammation, immuno-mediated disease, anti-TNF-alpha, off-label use.
Current Drug Safety
Title:Biologic Therapy in Inflammatory and Immunomediated Skin Diseases: Safety Profile
Volume: 11 Issue: 1
Author(s): Giulia Ganzetti, Anna Campanati, E. Molinelli and A. Offidani
Affiliation:
Keywords: Inflammation, immuno-mediated disease, anti-TNF-alpha, off-label use.
Abstract: Biologic treatments have modified the therapeutic armamentarium in the treatment of many dermatological and non- dermatological diseases and data on literature have widely focused on the efficacy and safety of TNF-alpha inhibitors in psoriasis.
Although the etiopathogenesis has not completely elucidated, inflammation appears the lait motif unifying the immune-pathogenesis of diverse skin disease, as atopic dermatitis, alopecia areata and hidradenitis suppurativa.
Actually, data on the off-label use of biologics in cutaneous immune-mediated inflammatory diseases are scarce and restricted to anecdotal cases and case series.
The present review aims to evidence the major off- label use of TNF-alpha inhibitors in dermatology.
Export Options
About this article
Cite this article as:
Ganzetti Giulia, Campanati Anna, Molinelli E. and Offidani A., Biologic Therapy in Inflammatory and Immunomediated Skin Diseases: Safety Profile, Current Drug Safety 2016; 11 (1) . https://dx.doi.org/10.2174/1574886310666151014121732
DOI https://dx.doi.org/10.2174/1574886310666151014121732 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Tumor Stroma as a Target in Cancer
Current Cancer Drug Targets The Use of the Inhibitory Receptors for Modulating the Immune Responses
Current Pharmaceutical Design The Putative Adverse Effects of Bisphenol A on Autoimmune Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets Exploring Pharmacological Significance of Chalcone Scaffold: A Review
Current Medicinal Chemistry Progress of HDAC Inhibitor Panobinostat in the Treatment of Cancer
Current Drug Targets Role of Plasmacytoid Dendritic Cells in Lung-Associated Inflammation
Recent Patents on Inflammation & Allergy Drug Discovery Metabolomics of Serum Peptides
Protein & Peptide Letters Drug Disposition in Pathophysiological Conditions
Current Drug Metabolism Side Effects of AAS Abuse: An Overview
Mini-Reviews in Medicinal Chemistry Pharmacophore and Binding Analysis of Known and Novel B-RAF Kinase Inhibitors
Current Medicinal Chemistry Adjuvant Zoledronic Acid Reduces Disease Recurrence in Breast Cancer: Antitumor Effects on the Seed and the Soil
Current Cancer Therapy Reviews Immunotherapy in Invasive Fungal Infection - Focus on Invasive Aspergillosis
Current Pharmaceutical Design Pharmacogenomics – Implications in the Development of HIV-Associated Brain Disease
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Bladder Cancer and Stem Cells
Current Signal Transduction Therapy Hitting the Golden TORget: Curcumin’s Effects on mTOR Signaling
Anti-Cancer Agents in Medicinal Chemistry Emerging Role of Wnt/Beta-Catenin Signalling Pathways in Cancer Progression and Role of Small Molecule Tankyrase Inhibitors in Combating Multistage Cancers
Current Cancer Therapy Reviews Functional Nanoplatforms for Enhancement of Chemotherapeutic Index
Anti-Cancer Agents in Medicinal Chemistry Intracellular Fate of Peptide-Mediated Delivered Cargoes
Current Pharmaceutical Design The Cyclin-Dependent Kinase Inhibitor p21CDKN1A as a Target of Anti-Cancer Drugs
Current Cancer Drug Targets Drug Discovery in Ovarian Cancer
Recent Patents on Anti-Cancer Drug Discovery